Clynes RA, Towers TL, Presta LG, et al: Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 6:443-6, 2000 39. Musolino A, Naldi N, Bortesi B, et al: Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 26:1789- 96, 2008 40. Park S, Jiang Z, Mortenson ED, et al: The therapeutic effect of anti- HER2/neu antibody depends on both innate and adaptive immunity. Cancer Cell 18:160-70, 2010 41. Taylor C, Hershman D, Shah N, et al: Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy. Clin Cancer Res 13:5133-43, 2007 42. Knutson KL, Perez EA, Ballman KV, et al: Generation of adaptive HER2- specific immunity in HER2 breast cancer patients by addition of trastuzumab to chemotherapy in the adjuvant setting: NCCTG (Alliance) study N9831, J Clin Oncol (Meeting Abstracts), 2013, pp 522 43. Inoue M, Mimura K, Izawa S, et al: Expression of MHC Class I on breast cancer cells correlates inversely with HER2 expression. Oncoimmunology 1:1104-1110, 2012 49 Protocol: 2014-0443 Version 2.1 Version Date: 11 April 2016 44. Mittendorf EA, Storrer CE, Shriver CD, et al: Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 13:1085-98, 2006 45. Disis ML, Wallace DR, Gooley TA, et al: Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27:4685-92, 2009 46. Mittendorf E, Perez S, Tzonis P, et al: Abstract P2-20-03: Combination Immunotherapy for Breast Cancer Patients: Safety and Immunologic Data from a Phase II Trial Administering a HER2/neu-Derived Peptide vaccine (AE37+GM- CSF) Sequentially or Concurrently with Trastuzumab in the Adjuvant Setting. Cancer Research 70:P2-20-03, 2011 47. Disis ML, Goodell V, Schiffman K, et al: Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 24:571-8, 2004 48. Khatcheressian JL, Hurley P, Bantug E, et al: Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31:961-5, 2013 50 Protocol: 2014-0443 Version 2.1 Version Date: 11 April 2016 Appendix A Trial Schema Protocol: 2014-0443 Version 2.1 Version Date: 11 April 2016 51 Appendix B Vaccination Timeline 52 Protocol: 2014-0443 Version 2.1 Version Date: 11 April 2016 Appendix C NCI Common Terminology Criteria for Adverse Events, v4.03 obtained from http://ctep.cancer.gov/forms/CTCAEv4.03.pdf http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06 14_QuickReference_8.5x11.pdf 53 Protocol: 2014-0443 Version 2.1 Version Date: 11 April 2016 Appendix D 2014-0443 Phase II Trial of combination immunotherapy with nelipepimut-S + GM-CSF (NeuVax™) and trastuzumab in high-risk HER2+ breast cancer patients Dosing Preparation Instructions Dosing Summary: The study treatment is 1000 mcg of E75 peptide (nelipepimut-S) mixed with 250 mcg of lyophilized Leukine® (sargramostim, GM-CSF) or placebo (water for injection) mixed with Leukine, administered in four separate 0.4 mL intradermal injections. The E75 peptide is provided as 1.5 mg/mL of E75 acetate (contains a 1.42 mg/mL solution of the E75 peptide).